|
|
|
Search for: "Celgene"
Celgene Corporation Announces Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer
HSMN NewsFeed,
26 Aug 2010:
Biopharmaceuticals, Personnel
[Celgene]
|
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
HSMN NewsFeed,
20 Aug 2010:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, lenalidomide, myelodysplastic syndrome]
|
Human Genome Sciences Names Tuomo Pätsi Vice President, HGS Europe
HSMN NewsFeed,
13 Aug 2010:
Biopharmaceuticals, Personnel
[Human Genome Sciences]
|
Celgene to Acquire Abraxis BioScience Inc.
HSMN NewsFeed,
30 Jun 2010:
Biopharmaceuticals, Mergers & Acquisitions
[Celgene, Abraxis BioScience]
|
Celgene Corporation Announces Senior Management Succession
HSMN NewsFeed,
29 Apr 2010:
Biopharmaceuticals, Personnel
[Celgene]
|
Satori Pharmaceuticals Adds Key Senior Members to its Leadership Team
HSMN NewsFeed,
26 Apr 2010:
Biopharmaceuticals, Personnel
[Satori Pharmaceuticals]
|
Ligand Completes Acquisition of Metabasis
HSMN NewsFeed,
28 Jan 2010:
Biopharmaceuticals, Mergers & Acquisitions
[Ligand Pharmaceuticals, Metabasis Therapeutics]
|
PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
HSMN NewsFeed,
19 Jan 2010:
Biopharmaceuticals
[PTC Therapeutics, ataluren, PTC124, Duchenne/Becker, muscular dystrophy]
|
GlobeImmune Announces $17.5 Million Series E Financing
HSMN NewsFeed,
19 Jan 2010:
Biopharmaceuticals, Venture Capital
[GlobeImmune]
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
HSMN NewsFeed,
15 Jan 2010:
Biopharmaceuticals, Mergers & Acquisitions
[Celgene, Gloucester Pharmaceuticals]
|
Acceleron Pharma Expands Management Team with Two New Appointments
HSMN NewsFeed,
22 Dec 2009:
Biopharmaceuticals, Personnel
[Acceleron Pharma]
|
PTC Therapeutics Closes $50 Million Financing
HSMN NewsFeed,
22 Dec 2009:
Biopharmaceuticals, Venture Capital
[PTC Therapeutics]
|
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
HSMN NewsFeed,
18 Dec 2009:
Biopharmaceuticals, Regulatory
[Ligand Pharmaceuticals, GlaxoSmithKline, Revolade, eltrombopag, Promacta]
|
Celgene to Acquire Gloucester Pharmaceuticals
HSMN NewsFeed,
7 Dec 2009:
Biopharmaceuticals, Oncology, Mergers & Acquisitions
[Celgene, Gloucester Pharmaceuticals, ISTODAX, romidepsin, lymphoma]
|
Wound Management Technologies' CellerateRx Receives further Press at VA Conference; Statistical Evidence Mounts
HSMN NewsFeed,
1 Dec 2009:
Devices, Wound Care
[Wound Management Technologies, CellerateRx, collagen]
|
NeurogesX Expands Commercial Operations Leadership Team
HSMN NewsFeed,
5 Nov 2009:
Biopharmaceuticals, Personnel
[NeurogesX, Qutenza, capsaicin]
|
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
HSMN NewsFeed,
5 Nov 2009:
Biopharmaceuticals, Personnel
[InterMune, pirfenidone]
|
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
HSMN NewsFeed,
4 Nov 2009:
Biopharmaceuticals, Oncology
[Acceleron Pharma, ACE-041, angiogenesis, TGF-β, TGF-beta]
|
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
HSMN NewsFeed,
27 Oct 2009:
Biopharmaceuticals, Mergers & Acquisitions
[Ligand Pharmaceuticals, Metabasis]
|
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
HSMN NewsFeed,
10 Sep 2009:
Biopharmaceuticals
[PTC Therapeutics, ataluren, cystic fibrosis]
|
Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
HSMN NewsFeed,
25 Aug 2009:
Biopharmaceuticals, Oncology, Litigation
[Celgene, thalidomide, THALOMID, REVLIMID, multiple myeloma]
|
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
HSMN NewsFeed,
1 Jun 2009:
Biopharmaceuticals, Personnel
[PTC Therapeutics]
|
Clovis Oncology Raises $145 Million in Start-Up Financing
HSMN NewsFeed,
21 May 2009:
Biopharmaceuticals, Oncology, Venture Capital
[Clovis Oncology]
|
Ligand Announces Approval in Europe of CONBRIZA for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
HSMN NewsFeed,
27 Apr 2009:
Biopharmaceuticals, Regulatory
[Ligand Pharmaceuticals, Wyeth, CONBRIZA, bazedoxifene, osteoporosis]
|
FABLYN Approved in Europe for the Treatment of Osteoporosis
HSMN NewsFeed,
24 Mar 2009:
Biopharmaceuticals, Regulatory
[Ligand Pharmaceuticals, Pfizer, FABLYN, lasofoxifene, osteoporosis]
|
Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
HSMN NewsFeed,
2 Mar 2009:
Biopharmaceuticals, Personnel
[Pearl Therapeutics]
|
REVLIMID Receives Preliminary Positive Recommendation from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales
HSMN NewsFeed,
30 Jan 2009:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sàrl, Celgene, REVLIMID, multiple myeloma]
|
NovaBay (NBY) Appoints Harry F. Hixson, Jr., PhD, Former Amgen President/Chief Operating Officer to Its Board of Directors
HSMN NewsFeed,
20 Jan 2009:
Biopharmaceuticals, Personnel
[NovaBay Pharmaceuticals]
|
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
HSMN NewsFeed,
8 Jan 2009:
Biopharmaceuticals, Personnel
[Amicus Therapeutics]
|
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
HSMN NewsFeed,
24 Oct 2008:
Biopharmaceuticals, Regulatory
[Celgene, Celgene International Sàrl, VIDAZA, azacitidine]
|
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
HSMN NewsFeed,
6 Oct 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sarl, REVLIMI, lenalidomide, multiple myeloma]
|
Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy
HSMN NewsFeed,
4 Sep 2008:
Biopharmaceuticals, FDA, Oncology
[Celgene, Amrubicin, fast track designation]
|
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
HSMN NewsFeed,
21 Aug 2008:
Biopharmaceuticals, Oncology, FDA
[Celgene, myelodysplastic syndromes, VIDAZA]
|
GPC Biotech Reports that Celgene to Terminate Co-Development and License Agreement for Satraplatin
HSMN NewsFeed,
6 Aug 2008:
Biopharmaceuticals, Licensing, Distribution
[GPC Biotech, Celgene, satraplatin]
|
Pharmacopeia Announces Further Reductions to Workforce
HSMN NewsFeed,
5 Aug 2008:
Biopharmaceuticals
[Pharmacopeia]
|
Vertos Medical Inc. Completes Series C Financing
HSMN NewsFeed,
17 Jul 2008:
Devices, Neurosurgery, Orthopaedic, Venture Capital
[Vertos Medical]
|
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
HSMN NewsFeed,
8 Jul 2008:
Biopharmaceuticals, Personnel
[Royalty Pharma]
|
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
HSMN NewsFeed,
8 Jul 2008:
Biopharmaceuticals
[Novartis, Focalin XR, Focalin, ADHD, dexmethylphenidate]
|
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
HSMN NewsFeed,
13 Jun 2008:
Biopharmaceuticals, Oncology
[Celgene International Sarl, VIDAZA, azacitidine, myelodysplastic syndromes]
|
VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU
HSMN NewsFeed,
13 Jun 2008:
Biopharmaceuticals, Oncology
[Celgene International Sarl, VIDAZA, azacitidine, myelodysplastic syndromes]
|
Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
HSMN NewsFeed,
3 Jun 2008:
Biopharmaceuticals, Oncology
[Celgene, VIDAZA, myelodysplastic syndromes]
|
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
HSMN NewsFeed,
2 Jun 2008:
Biopharmaceuticals, Oncology
[MethylGene, MGCD0103, Hodgkins Lymphoma]
|
Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes
HSMN NewsFeed,
2 Jun 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, Lenalidomide, myelodysplastic syndromes]
|
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
HSMN NewsFeed,
2 Jun 2008:
Biopharmaceuticals, Oncology
[GPC Biotech, satraplatin, SPARC trial, prostate cancer]
|
Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting
HSMN NewsFeed,
1 Jun 2008:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
ImmuneRegen(R) and BioCure Collaborate on Novel Wound-Healing Product
HSMN NewsFeed,
24 Apr 2008:
Devices, Wound Care
[ImmuneRegen BioSciences, BioCure, Homspera, GelSpray]
|
Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union
HSMN NewsFeed,
21 Apr 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sarl, Thalidomide, Pharmion, multiple myeloma, REVLIMID]
|
Amrubicin is Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer
HSMN NewsFeed,
11 Apr 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sarl, amrubicin, orphan drug designation, lung cancer]
|
Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
HSMN NewsFeed,
10 Apr 2008:
Biopharmaceuticals, Personnel
[Pharmacopeia]
|
Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
7 Apr 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sarl, Thalidomide, Thalidomide Pharmion, multiple myeloma]
|
Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
HSMN NewsFeed,
25 Mar 2008:
Biopharmaceuticals, Oncology, FDA
[Celgene, Amrubicin, orphan drug designation, small cell lung cancer]
|
Celgene Completes $2.9 Billion Acquisition of Pharmion
HSMN NewsFeed,
7 Mar 2008:
Biopharmaceuticals, Mergers & Acquisitions
[Celgene, Pharmion]
|
Pharmacopeia Announces Management Team Changes
HSMN NewsFeed,
28 Feb 2008:
Biopharmaceuticals, Personnel
[Pharmacopeia]
|
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
HSMN NewsFeed,
19 Feb 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sarl, lenalidomide, orphan drug designation]
|
Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes
HSMN NewsFeed,
24 Jan 2008:
Biopharmaceuticals, Regulatory
[Celgene International Sarl, REVLIMID, multiple myeloma, Lenalidomide]
|
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
HSMN NewsFeed,
24 Jan 2008:
Biopharmaceuticals, Oncology, Regulatory
[Pharmion, Thalidomide Pharmion, Thalidomide, multiple myeloma]
|
SWOG Phase III Trial Reports REVLIMID(R) (lenalidomide) Plus Dexamethasone Achieves Superior Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients
HSMN NewsFeed,
9 Dec 2007:
Biopharmaceuticals, Oncology
[Celgene, Celgene International Sàrl, REVLIMID, lenalidomide, multiple myeloma]
|
REVLIMID(R) (Lenalidomide) Plus Low-Dose Dexamethasone Achieves Unprecedented Survival Rate in ECOG Phase III Trial in Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
9 Dec 2007:
Biopharmaceuticals, Oncology
[Celgene, Celgene International Sàrl, REVLIMID, lenalidomide, multiple myeloma]
|
Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia
HSMN NewsFeed,
30 Nov 2007:
Biopharmaceuticals, Regulatory
[Celgene, lenalidomide, REVLIMID, chronic lymphocytic leukemia]
|
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
HSMN NewsFeed,
18 Nov 2007:
Biopharmaceuticals, Oncology, Mergers & Acquisitions
[Celgene, Pharmion, Vidaza]
|
Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
HSMN NewsFeed,
12 Nov 2007:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, Celgene International Sarl, REVLIMID, lenalidomide, multiple myeloma]
|
GlobeImmune Raises $41.2 Million in Series C Financing
HSMN NewsFeed,
26 Sep 2007:
Biopharmaceuticals, Venture Capital
[GlobeImmune, Tarmogen]
|
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
HSMN NewsFeed,
17 Sep 2007:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, Chronic Lymphocytic Leukemia]
|
EntreMed Raises $20 Million to Support Clinical Development Program
HSMN NewsFeed,
17 Sep 2007:
Biopharmaceuticals, Venture Capital
[EntreMed]
|
PTC Therapeutics Announces $20 Million Strategic Investment From Celgene Corporation
HSMN NewsFeed,
13 Sep 2007:
Biopharmaceuticals
[PTC Therapeutics, Celgene]
|
OpGen Announces $23.6 Million Series A Financing
HSMN NewsFeed,
12 Sep 2007:
Diagnostics, Venture Capital
[OpGen]
|
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
HSMN NewsFeed,
4 Sep 2007:
Biopharmaceuticals, Regulatory, Oncology
[Celgene International Sarl, Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
Celgene Corporation Elects Ernest Mario to Board of Directors
HSMN NewsFeed,
23 Aug 2007:
Biopharmaceuticals, Personnel
[Celgene]
|
Nereus Pharmaceuticals Raises $45 Million in Series D-2 Financing
HSMN NewsFeed,
9 Aug 2007:
Biopharmaceuticals, Venture Capital
[Nereus Pharmaceuticals]
|
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
HSMN NewsFeed,
19 Jun 2007:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology, Regulatory
[Pharmion, Thalidomide, multiple myeloma]
|
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
HSMN NewsFeed,
15 May 2007:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, dexamethasone, multiple myeloma]
|
Royalty Pharma Acquires a Portion of New York University's Royalty Interest in Remicade(R) for $650 Million
HSMN NewsFeed,
4 May 2007:
Biopharmaceuticals
[Royalty Pharma, Remicade]
|
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
HSMN NewsFeed,
4 Apr 2007:
Biopharmaceuticals, Oncology
[Celgene, ECOG, lenalidomide, REVLIMID]
|
Rincon Pharmaceuticals Appoints Dr. Peter B. Heifetz as Chief Scientific Officer, Drs. Jacqueline J. Johnson and Alan J. Lewis to Board of Directors, and Drs. Katherine S. Bowdish and Mich B. Hein to Scientific Advisory Board
HSMN NewsFeed,
28 Mar 2007:
Biopharmaceuticals, Personnel
[Rincon Pharmaceuticals]
|
AVI BioPharma Chairman and CEO Resigns
HSMN NewsFeed,
28 Mar 2007:
Biopharmaceuticals, Personnel
[AVI BioPharma]
|
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
HSMN NewsFeed,
23 Mar 2007:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
HSMN NewsFeed,
1 Mar 2007:
Biopharmaceuticals, Oncology, Regulatory
[Pharmion, Thalidomide, multiple myeloma]
|
Barr Confirms Generic Thalomid(R) Suit Filed
HSMN NewsFeed,
23 Jan 2007:
Biopharmaceuticals, Generics, Litigation
[Barr Pharmaceuticals, Celgene, Thalomid, thalidomide]
|
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
HSMN NewsFeed,
23 Jan 2007:
Biopharmaceuticals, Oncology, Regulatory
[Pharmion, Thalidomide, Thalidomide Pharmion, multiple myeloma]
|
NCCN Updates Antiemesis Guidelines
HSMN NewsFeed,
8 Jan 2007:
Biopharmaceuticals, Oncology
[NCCN, Antiemesis Guidelines]
|
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
HSMN NewsFeed,
28 Dec 2006:
Biopharmaceuticals, Oncology
[Keryx Biopharmaceuticals, KRX-0401, perifosine, Revlimid, lenalidomide, Celgene]
|
Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg Application
HSMN NewsFeed,
26 Dec 2006:
Biopharmaceuticals, Generics, Oncology, FDA
[Barr Pharmaceuticals, thalidomide, Celgene, Thalomid]
|
Celgene Notified of ANDA Filing for Thalidomide
HSMN NewsFeed,
26 Dec 2006:
Biopharmaceuticals, Generics, FDA
[Celgene, Barr Pharmaceuticals, thalidomide, THALOMID]
|
Barr Confirms Generic Thalomid(R) Capsule Application
HSMN NewsFeed,
13 Dec 2006:
Biopharmaceuticals, Generics, FDA
[Barr Pharmaceuticals, Celgene, Thalomid, thalidomide]
|
Celgene Notified of ANDA Filing for Thalidomide
HSMN NewsFeed,
13 Dec 2006:
Biopharmaceuticals, Generics, FDA, Litigation
[Celgene, Barr Pharmaceuticals, THALOMID, thalidomide]
|
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed,
8 Dec 2006:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, multiple myeloma, lymphoma, leukemia]
|
Celgene Appoints Thomas O. Daniel, M.D. as President of Global Research
HSMN NewsFeed,
7 Dec 2006:
Biopharmaceuticals, Personnel
[Celgene]
|
Celgene Names David W. Gryska Chief Financial Officer
HSMN NewsFeed,
7 Dec 2006:
Biopharmaceuticals, Personnel
[Celgene]
|
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA(R) From AstraZeneca and CAT
HSMN NewsFeed,
26 Oct 2006:
Biopharmaceuticals
[Royalty Pharma, Abbott, AstraZeneca, HUMIRA, adalimumab]
|
NeoStem, Inc. Appoints Julio C. Guerra, MD, ABP, as Director of Sales and Marketing
HSMN NewsFeed,
26 Oct 2006:
Regenerative Medicine, Personnel
[NeoStem]
|
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
HSMN NewsFeed,
2 Oct 2006:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, non-Hodgkins lymphoma]
|
QuantRx(R) Biomedical Appoints Former FDA Commissioner Dr. Arthur Hull Hayes, Jr. to Board of Directors
HSMN NewsFeed,
19 Sep 2006:
Diagnostics, Personnel
[QuantRx Biomedical]
|
The International Myeloma Foundation Says REVLIMID(R) Approval for Multiple Myeloma Can Be Life-Changing for Cancer Patients
HSMN NewsFeed,
29 Jun 2006:
Biopharmaceuticals, Oncology, FDA
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
HSMN NewsFeed,
29 Jun 2006:
Biopharmaceuticals, Oncology, FDA
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
Proprius Pharmaceuticals Appoints David W. Anderson, Ph.D. as Chief Scientific Officer
HSMN NewsFeed,
12 Jun 2006:
Biopharmaceuticals, Personnel
[Proprius Pharmaceuticals]
|
REVLIMID(R) (Lenalidomide) Evaluated as Combination Oral Treatment Regimen in Elderly Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide]
|
THALOMID(R) (Thalidomide) Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Oncology
[Celgene, thalidomide, MM-003, multiple myeloma]
|
Thalidomide Survival Data Evaluated in Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Personnel
[Celgene, thalidomide, multiple myeloma]
|
Thalomid(R) sNDA Granted FDA Approval For Treatment of Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
25 May 2006:
Biopharmaceuticals, Oncology, FDA
[Celgene, THALOMID, thalidomide, multiple myeloma]
|
REVLIMID(R) Marketing Authorization Application Accepted by EMEA for Review
HSMN NewsFeed,
7 Apr 2006:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, multiple myeloma, myelodysplastic syndromes]
|
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of Relapsed or Refractory Multiple Myeloma
HSMN NewsFeed,
3 Mar 2006:
Biopharmaceuticals, Oncology, FDA
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
EntreMed Raises $30 Million in Private Placement
HSMN NewsFeed,
3 Feb 2006:
Biopharmaceuticals
[EntreMed]
|
Pharmion Provides EU Registration Strategy Update for Thalidomide
HSMN NewsFeed,
10 Jan 2006:
Biopharmaceuticals, Oncology, Regulatory
[Pharmion, Celgene, thalidomide, multiple myeloma]
|
THALOMID(R) Pivotal Phase III Multiple Myeloma Trial Reaches Pre-Specified Interim Endpoint
HSMN NewsFeed,
9 Jan 2006:
Biopharmaceuticals
[Celgene, THALOMID, thalidomide]
|
|
|
 |
Additional items found:
The Network Archive contains
93 additional items
matching: Celgene
<< Members - click the icon at left to display. |
|
| |
|
|
|
|
Public
Feeds 
Full text >>